Close Menu
    Obesity rates plateaued or slightly declined in several high-income countries, while obesity continued rising across most low-income and middle-income countries despite already surpassing prevalence levels seen in wealthier nations, according to data from 232 million people between 1980 and 2024
    Science

    Obesity rates plateaued or slightly declined in several high-income countries, while obesity continued rising across most low-income and middle-income countries despite already surpassing prevalence levels seen in wealthier nations, according to data from 232 million people between 1980 and 2024


    Obesity rates plateaued or slightly declined in several high-income countries, while obesity continued rising across most low-income and middle-income countries despite already surpassing prevalence levels seen in wealthier nations, according to data from 232 million people between 1980 and 2024

    https://www.nature.com/articles/s41586-026-10383-0

    Share.
    View 10 Comments

    10 Comments

    2. Piruluk on

      GLP1, I noticed that the healthy at all size moment greatly shrunk since that thing became widespread

    3. Weep4Thee on

      It’s almost like one group has something to live for and the other doesn’t…

    4. thinkB4WeSpeak on

      Only thing holding that plateau is people using ozepect and other drugs like that

    5. Bill_Nihilist on

      Considering how negatively obesity impacts fertility, it will be interesting to see how this relates to the fertility crisis now and in the future.

    7. Rameez_Raja on

      India is about to start producing generic GLP1 imminently. I expect rates to crater pretty much everywhere once that hits the market at scale.

      Edit: whoops. I mentioned India in a comment, gotta mute replies now.

    9. SenescenseSteel on

      We are allready past GLP-1 and entering Retatrutide domain (GLP-1, GIP, Glucagon) what a time to be (fat) and alive. And you still have ms people trying to diminish peptides and frame them as scams all together.

    10. Siglyr on

      So there’s a lot of comments about GLP-1 but I’m not sure that’s relevant in the study? What they call “recent decline” is from about 2010, no Ozempic yet. And the countries are France, Italy, and Denmark. + this includes children, which are not on medication. As they talk about in the paper, it’s linked to economies. I don’t know if there are studies on the impact of GLP-1 yet, might be too early. These population-wide datasets need years if not decades to show significant trends